[go: up one dir, main page]

MA46176A - Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci - Google Patents

Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci

Info

Publication number
MA46176A
MA46176A MA046176A MA46176A MA46176A MA 46176 A MA46176 A MA 46176A MA 046176 A MA046176 A MA 046176A MA 46176 A MA46176 A MA 46176A MA 46176 A MA46176 A MA 46176A
Authority
MA
Morocco
Prior art keywords
azetidin
triazolo
compositions
methods
pyridinyl compounds
Prior art date
Application number
MA046176A
Other languages
English (en)
Inventor
Limin Cheng
Yun-Xing Cheng
Simon Charles Goodacre
Rongbao Hua
F Anthony Romero
Mark Zak
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA46176A publication Critical patent/MA46176A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA046176A 2016-09-06 2017-09-02 Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci MA46176A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016098215 2016-09-06

Publications (1)

Publication Number Publication Date
MA46176A true MA46176A (fr) 2019-07-17

Family

ID=59761965

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046176A MA46176A (fr) 2016-09-06 2017-09-02 Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci

Country Status (19)

Country Link
US (3) US20190202822A1 (fr)
EP (2) EP3510030B1 (fr)
JP (1) JP7050761B2 (fr)
KR (1) KR20190045302A (fr)
CN (1) CN109890817B (fr)
AU (1) AU2017324281A1 (fr)
BR (1) BR112019004486A2 (fr)
CA (1) CA3035712A1 (fr)
CL (1) CL2019000568A1 (fr)
CO (1) CO2019002171A2 (fr)
CR (1) CR20190118A (fr)
IL (1) IL265153A (fr)
MA (1) MA46176A (fr)
MX (1) MX2019002627A (fr)
PE (1) PE20190632A1 (fr)
PH (1) PH12019500478A1 (fr)
RU (1) RU2019109570A (fr)
SG (1) SG11201901954XA (fr)
WO (1) WO2018046409A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020257143A1 (fr) 2019-06-18 2020-12-24 Genentech, Inc. Inhibiteurs éther-aryl-pyrazolopyrimidine de kinases jak et leurs utilisations
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024148184A1 (fr) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Composés et procédés pour la préparation d'inhibiteurs de jak
WO2024148186A1 (fr) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Polymorphes d'un inhibiteur de jak1/tyk2 et leurs utilisations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO1997002289A1 (fr) 1995-07-06 1997-01-23 Zeneca Limited Inhibiteurs peptidiques de la fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (fr) 2001-03-16 2002-09-18 Pfizer Products Inc. Dérivés de purine pour le traitement de l'ischémie
EP1458682B1 (fr) 2001-12-20 2006-08-30 Bayer HealthCare AG Derives de 1,4-dihydro-1,4-diphenylpyridine
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
BRPI0910021A2 (pt) * 2008-06-20 2015-09-01 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinas em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
WO2010010184A1 (fr) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak
WO2010141796A2 (fr) * 2009-06-05 2010-12-09 Cephalon, Inc. Préparation et utilisation de dérivés de 1,2,4-triazolo[1,5a]pyridine
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
PL3786162T3 (pl) * 2013-05-17 2024-04-08 Incyte Holdings Corporation Pochodne bipirazolu jako inhibitory jak
SG11201601707PA (en) * 2013-09-05 2016-04-28 Hoffmann La Roche Triazolopyridine compounds, compositions and methods of use thereof
CN107428750A (zh) * 2015-03-04 2017-12-01 豪夫迈·罗氏有限公司 三唑并吡啶化合物及其使用方法

Also Published As

Publication number Publication date
US20190202822A1 (en) 2019-07-04
US20230242530A1 (en) 2023-08-03
RU2019109570A3 (fr) 2020-10-08
PH12019500478A1 (en) 2019-12-02
JP2019526593A (ja) 2019-09-19
WO2018046409A1 (fr) 2018-03-15
AU2017324281A1 (en) 2019-03-21
EP4198036A1 (fr) 2023-06-21
JP7050761B2 (ja) 2022-04-08
CR20190118A (es) 2019-04-30
BR112019004486A2 (pt) 2019-05-28
US20200270248A1 (en) 2020-08-27
CL2019000568A1 (es) 2019-07-12
RU2019109570A (ru) 2020-10-08
SG11201901954XA (en) 2019-04-29
MX2019002627A (es) 2019-10-30
CN109890817A (zh) 2019-06-14
CO2019002171A2 (es) 2019-05-21
EP3510030B1 (fr) 2023-03-22
CN109890817B (zh) 2022-06-17
PE20190632A1 (es) 2019-04-26
EP3510030A1 (fr) 2019-07-17
KR20190045302A (ko) 2019-05-02
CA3035712A1 (fr) 2018-03-15
IL265153A (en) 2019-05-30

Similar Documents

Publication Publication Date Title
HUS2200054I1 (hu) 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése
EP3500575C0 (fr) Forme cristalline de (s)-7-(1-acryloylpipéridin-4-yl)-2-(4-phénoxyphényle)-4,5,6,7-tétra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, sa préparation et ses utilisations
EP3370715A4 (fr) Composés chimères de ciblage de protéolyse et procédés de préparation et d'utilisation de ceux-ci
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
SI3107914T1 (sl) Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba
EP3374494A4 (fr) Compositions crispr et leurs méthodes d'utilisation pour la thérapie génique
SI3555097T1 (sl) Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz
EP3481402A4 (fr) Composés, compositions et méthodes de traitement de maladie
MA49570A (fr) Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak
EP3250572A4 (fr) Composés d'imidazo[1,2-a]pyridin-2-ylamine substitués, compositions pharmaceutiques et leurs méthodes d'utilisation
MA50045A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
EP3484504A4 (fr) Composés, compositions et méthodes de traitement de maladie
PL3597649T3 (pl) Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2
EP3504196A4 (fr) Procédés de préparation d'olaparib
EP3481827A4 (fr) Dérivés d'imidazo[1,2-a]pyridine, leurs procédés de préparation et leur utilisation
MA50041A (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
IL254168A0 (en) Use of 3,2-dihydroimidazo[2,1-c]converted quinazolines
EP3455226A4 (fr) Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
MA47167A (fr) Composés pyrazolopyrimidine et leurs procédés d'utilisation
IL265791A (en) Compositions and methods for treating dry mouth
PT3500571T (pt) Compostos de imidazo[1,2-a] piridina, composições que os compreendem, métodos para o uso no tratamento de doenças e seus métodos de preparação
MA46176A (fr) Composés de 8-(azétidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyle, compositions et procédés d'utilisation de ceux-ci
EP3349755A4 (fr) Formulations de nicotine, leurs procédés de préparation et d'utilisation
EP3122381A4 (fr) Utilisation d'antagonistes de la kinase 1 apparentée au récepteur de l'activine (alk-1) dans le traitement du cancer
LT3230289T (lt) 7-(morfolinil)-2-(n-piperazinil)metiltieno[2, 3-c]piridino dariniai kaip priešvėžiniai vaistai